Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial

Background: The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus. Materials and Methods: In this parallel randomized clinical trial study, overall 48 patients...

Full description

Bibliographic Details
Main Authors: Fariba Iraji, Ali Asilian, Ahmad Saeidi, Amir Hossein Siadat, Ali Reza Saeidi, Akbar Hassanzadeh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Advanced Biomedical Research
Subjects:
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2013;volume=2;issue=1;spage=76;epage=76;aulast=Iraji
id doaj-d7fa82d1ee984517b6468135dc912d4e
record_format Article
spelling doaj-d7fa82d1ee984517b6468135dc912d4e2020-11-25T00:43:20ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752277-91752013-01-0121767610.4103/2277-9175.115798Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trialFariba IrajiAli AsilianAhmad SaeidiAmir Hossein SiadatAli Reza SaeidiAkbar HassanzadehBackground: The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus. Materials and Methods: In this parallel randomized clinical trial study, overall 48 patients completed the study. 25 patients were treated with subcutaneous enoxaparin 5 mg weekly and 23 patients with 0.5 mg/kg prednisone orally daily until complete remission or a maximum of 8 weeks. The results of itching severity, extent of active lesions and drug side effects were compared. In remission, patients were followed for 6 months for recurrent lesions. Results: In enoxaparin group, 8 patients (32%) had complete remission and 10 patients (40%) had partial improvement. In the oral prednisone group, 16 patients (69.6%) had complete remission and 6 patients (26.1%) had partial improvement (P = 0.005). Average size of active lesions in both groups decreased significantly after treatment, but analysis of covariance showed that the mean lesion size after treatment in the oral prednisone group was significantly lower than the enoxaparin group (P = 0.005). The relapse rate from improved patients in the enoxaparin group was 6 (33%) and in oral prednisone group was 9 (40.9%, P = 0.083). In the enoxaparin group no serious complications was seen. But 22% in the oral prednisone group show side effect, the most common complications were dyspepsia. Conclusion: Low dose enoxaparin on lichen Planus have therapeutic effect and is important for the least side effects but not as much as oral prednisone. But it could be accepted as an alternative treatment.http://www.advbiores.net/article.asp?issn=2277-9175;year=2013;volume=2;issue=1;spage=76;epage=76;aulast=IrajiEnoxaparinlichen planuslow molecular weight heparinprednisone
collection DOAJ
language English
format Article
sources DOAJ
author Fariba Iraji
Ali Asilian
Ahmad Saeidi
Amir Hossein Siadat
Ali Reza Saeidi
Akbar Hassanzadeh
spellingShingle Fariba Iraji
Ali Asilian
Ahmad Saeidi
Amir Hossein Siadat
Ali Reza Saeidi
Akbar Hassanzadeh
Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
Advanced Biomedical Research
Enoxaparin
lichen planus
low molecular weight heparin
prednisone
author_facet Fariba Iraji
Ali Asilian
Ahmad Saeidi
Amir Hossein Siadat
Ali Reza Saeidi
Akbar Hassanzadeh
author_sort Fariba Iraji
title Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
title_short Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
title_full Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
title_fullStr Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
title_full_unstemmed Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
title_sort comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; a clinical trial
publisher Wolters Kluwer Medknow Publications
series Advanced Biomedical Research
issn 2277-9175
2277-9175
publishDate 2013-01-01
description Background: The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus. Materials and Methods: In this parallel randomized clinical trial study, overall 48 patients completed the study. 25 patients were treated with subcutaneous enoxaparin 5 mg weekly and 23 patients with 0.5 mg/kg prednisone orally daily until complete remission or a maximum of 8 weeks. The results of itching severity, extent of active lesions and drug side effects were compared. In remission, patients were followed for 6 months for recurrent lesions. Results: In enoxaparin group, 8 patients (32%) had complete remission and 10 patients (40%) had partial improvement. In the oral prednisone group, 16 patients (69.6%) had complete remission and 6 patients (26.1%) had partial improvement (P = 0.005). Average size of active lesions in both groups decreased significantly after treatment, but analysis of covariance showed that the mean lesion size after treatment in the oral prednisone group was significantly lower than the enoxaparin group (P = 0.005). The relapse rate from improved patients in the enoxaparin group was 6 (33%) and in oral prednisone group was 9 (40.9%, P = 0.083). In the enoxaparin group no serious complications was seen. But 22% in the oral prednisone group show side effect, the most common complications were dyspepsia. Conclusion: Low dose enoxaparin on lichen Planus have therapeutic effect and is important for the least side effects but not as much as oral prednisone. But it could be accepted as an alternative treatment.
topic Enoxaparin
lichen planus
low molecular weight heparin
prednisone
url http://www.advbiores.net/article.asp?issn=2277-9175;year=2013;volume=2;issue=1;spage=76;epage=76;aulast=Iraji
work_keys_str_mv AT faribairaji comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
AT aliasilian comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
AT ahmadsaeidi comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
AT amirhosseinsiadat comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
AT alirezasaeidi comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
AT akbarhassanzadeh comparisonoftherapeuticeffectoflowdoselowmolecularweightheparinenoxaparinvsoralprednisoneintreatmentofpatientswithlichenplanusaclinicaltrial
_version_ 1725279012516790272